Sponsors (5)
Introduced May 21, 2025 by Ro Khanna · Last progress May 21, 2025
The bill aims to make prescription drugs more affordable through price limits, open licensing, faster entry of generics/biosimilars, and greater transparency, but it trades off risks to pharmaceutical innovation, potential manufacturer countermeasures (higher launch prices or reduced supply), and new administrative and legal burdens.
Millions of patients (including Medicare and Medicaid beneficiaries and people with chronic conditions) would likely pay substantially lower prices because the bill enables HHS to identify 'excessive' drug prices, cap post‑exclusivity royalties, authorize open non‑exclusive licenses, and create clearer price benchmarks.
People who need costly brand-name drugs could gain faster access to lower-cost generics and biosimilars because the bill requires FDA to act on certain applications within set timelines and authorizes open licensing that lets competitors supply alternatives.
Consumers, payers, researchers, and policymakers would gain much greater transparency—public postings, annual reports, and detailed R&D/price data—helping identify overpriced drugs, evaluate policy, and inform purchasing decisions.
Pharmaceutical companies may reduce R&D investment and slow development of new therapies because revenues, exclusivity leverage, and expected returns could be diminished by price caps, penalties, and open licensing.
Manufacturers could respond to the law by raising launch prices, restricting U.S. supply, or pulling back on collaborations and joint R&D to avoid regulatory or antitrust exposure, which could increase costs or delay access for patients.
Government determinations, naming of drugs/manufacturers, use of others' regulatory data, and large statutory penalties would likely provoke legal challenges and disputes, delaying implementation and imposing litigation costs on taxpayers and firms.
Based on analysis of 8 sections of legislative text.
Directs HHS to identify excessive brand drug prices, void government exclusivities for those drugs, require open non‑exclusive licenses with capped royalties, mandate manufacturer reporting, and publish results.
Requires the HHS Secretary to run an annual review of brand-name drug prices, label drugs “excessive” if U.S. prices exceed a median of five reference countries or other factors indicate excess, and — for drugs found excessive — strip government-granted exclusivities and issue open, non-exclusive licenses so others can make or import the product. It sets rules for royalties, requires manufacturers to report detailed pricing and R&D data annually, creates a public database and reports, allows HHS to pursue damages for unlawful price increases, and bars coordinated anticompetitive actions that block access under the law.